Minerva Neurosciences, Inc - Common Stock (NERV)
Healthcare › Pharmaceutical Preparations
Price History
Feb 9, 2026 — Mar 10, 2026Investment Snapshot
- Trading 13% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 3/9 — signs of financial weakness
- ROE of 3.7% — below-average profitability
Minerva Neurosciences, Inc - Common Stock (NERV) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NASDAQ , with a market capitalisation of $261 million . Key value metrics: P/E ratio 4.4, Piotroski F-Score 3 out of 9 .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Minerva Neurosciences, Inc - Common Stock — Fundamental Analysis Summary
Minerva Neurosciences, Inc - Common Stock (NERV) is currently trading 13% above its Graham Number of $7.11, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries a low trailing P/E ratio of 4.4x.
On financial health, NERV shows a weak Piotroski F-Score of 3/9, a signal of deteriorating financial health, and modest return on equity of 3.7% (sector average: -19.8%).
StockPik's composite Value Score for NERV is 70/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
NERV shows earnings growing at 105%.